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Aims: The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15)
evaluates symptoms of sexual dysfunction in patients with multiple sclerosis (MS).
The objective of this study was to provide and validate a Dutch version of the
MSISQ-15 in patients with neurological disease such as MS and spinal cord injury
(SCI).
Methods: The linguistic validation process of the original English MSISQ-15 into
Dutch was performed according to standardized guidelines. Sexually active patients
with MS or spinal cord disorders, including SCI and cauda equine syndrome, who
visited a tertiary urology center or a rehabilitation center completed the MSISQ-15,
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in
women, or International Index of Erection Function (IIEF-15) in men at baseline
(test) and 2 weeks later (retest). A reference group recruited from a general medical
practice completed the questionnaires once. Data were analyzed for measurement
properties.
Results: Fifty-three patients with MS, 49 patients with spinal cord disorder, and 50
references were included. Content validity was adequate. Internal consistency
(Cronbach's alpha >0.8) and reproducibility (intraclass correlation coefficient >0.8)
of the MSISQ-15 were excellent. Patients’ MSISQ-15 scores were correlated with
severity of symptoms of sexual dysfunction measured by PISQ-12 or IIEF-15 and
confirmed positive rating for criterion validity. MSISQ-15 scores in patients were
higher than in references (on a scale of 15-75: 38.9 ± 11.4 vs 21.1 ± 5.4; P< 0.001),
indicating good construct validity.
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Conclusions: The Dutch MSISQ-15 is a reliable and valid measure to evaluate
symptoms of sexual dysfunction in patients with MS or with SCI.
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1 | INTRODUCTION
Living with neurological diseases such as multiple sclerosis
(MS) or spinal cord injury (SCI) might have significant
consequences for a person's sexual function and quality of
life.1,2 Sexual function can be assessed with patient-reported
outcome (PRO) measures, usually a questionnaire. This also
allows evaluating change over time.3
The Multiple Sclerosis Intimacy and Sexuality Ques-
tionnaire (MSISQ) evaluates symptoms of sexual dysfunc-
tion (SD) in MS patients, divided in three dimensions.
Categorized as primary SD are symptoms as a result of
neurologic changes that directly influence sexual function,
such as impaired genital sensation, erectile dysfunction,
orgasm dysfunction, decreased vaginal lubrication, and loss
or reduction of libido. Secondary SD includes symptoms
that arise from MS and indirectly influence sexual function,
such as muscle tightness, spasticity, bladder and bowel
dysfunction, pain, or discomfort in non-genital areas of the
body. Tertiary SD refers to the psychological, emotional,
social, and cultural aspects of MS that impact sexual
function.4,5 The original version of the MSISQ was in
English and consisted of 19 items and has been translated
and validated in the Persian6 and Portuguese languages.7 A
re-evaluation in a larger English cohort resulted in a
validated 15 item version.5
At this moment, no validated Dutch PRO measure is
available to assess SD in patients with a neurological disease.
Although theMSISQ-15 was developed for patients withMS,
the similarity between the SD symptoms of patients with MS
and those with SCI, as well as the similarity in treatment,
suggests that the instrument might work well in both
populations. This study is designed to provide a validated
Dutch version of the MSISQ-15 in patients with neurological
diseases.
2 | MATERIALS AND METHODS
This prospective validation study was approved by the
Institutional Ethics Committee (MEC-2016-370) and con-
ducted at a tertiary urology center and at a rehabilitation
center.
2.1 | Study populations and study design
2.1.1 | Patient group
Adults with MS or SCI or cauda equina syndrome were
eligible for inclusion if they spoke Dutch fluently.
Exclusion criteria consisted of dementia, mental retardation,
active malignant tumors, and no sexual activity during the
last 6 months. All potential eligible patients were informed
about the study and invited to participate by the treating
physician during a regular outpatient visit between
July 2016 and January 2018. After written informed consent
patients were asked to complete the questionnaires during
the inclusion visit (test) and 2 weeks later at home (retest).
Clinical characteristics of included patients were retrieved
from their medical files.
2.1.2 | Reference group
The reference group was invited from one general practi-
tioner's practice in January and February 2017. Exclusion
criteria consisted of Dutch language difficulties, neuro-
urological dysfunction, dementia, mental retardation, and no
sexual activity during the last 6 months. Since patients
visiting the general practitioner might have less severe health
issues, we considered these patients as proper reference
group. They provided written informed consent and com-
pleted the questionnaires once.
2.2 | Questionnaires
The questionnaire set consisted of the MSISQ-15, the EQ
visual-analogue scale (EQ-VAS), Pelvic Organ Prolapse/
Urinary Incontinence Sexual Questionnaire (PISQ-12), and
International Index of Erection Function (IIEF-15).
- The MSISQ-15 is a self-report measure that evaluates the
influence of MS symptoms on sexual activity and
satisfaction over the preceding 6 months. It is a valid
and reliable short version of the MSISQ-19 and consists
of 15 items. The MSISQ-15 is divided in three
dimensions to allow focus on the specific domain of
sexual concerns; primary SD (items 8, 12, 13, 14, 15),
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secondary SD (items 1, 2, 3, 4, 5), and tertiary SD (items
6, 7, 9, 10, 11). Each item is rated on a five-point Likert
scale ranging from 0 (never) to 5 (always). The total score
is the sum of the 15 items. The maximum total score is 75;
the higher the score the greater the impact of SD on
patients’ lives.5
- The PISQ-12 evaluates sexual function in heterosexual
women who suffer from urinary incontinence and/or pelvic
organ prolapse; it was not specifically designed for neuro-
urological patients. It is a valid and reliable short-form of
the PISQ-31, including 12 items.8 The PISQ-12 is recently
translated into Dutch and showed good reliability and
validity.9 Alteration of item 12 during the Dutch PISQ-12
validation study resulted in suboptimal answer options.
Without item 12 the Dutch version was still found to be
valid and reliable.We used the Dutch PISQ-12 without item
12. Responses are graded on a five-point Likert scale,
ranging from 0 (always) to 4 (never). Items 1-4 are reversely
scored. The maximum score is 44; higher scores indicate
better sexual function.9
- The IIEF-15 is a 15-item self-administered questionnaire
for the assessment of male sexual function, not specifically
for neuro-urological patients. The IIEF-15 addresses five
relevant domains of male sexual function: erectile function,
orgasmic function, sexual desire, intercourse satisfaction,
and overall satisfaction. Linguistic validation of the Dutch
IIEF-15 was conducted by the MAPI research Institute in
Lyon, France. Responses are graded on a scale for 0-5. The
maximum score is 75; higher scores indicate better sexual
function.10
- The EQ-VAS is part of the European Quality of Life-5
Dimensions questionnaire. The patient can indicate the
health state on the EQ-VAS, from 0 “the worst health you
can imagine” to 100 “the best health you can imagine.”
2.3 | Linguistic validation
The linguistic validation process of the original MSISQ-15
into the Dutch language was performed according to
standardized guidelines.11 Three professional translators
with Dutch as native language separately forward-translated
the English MSISQ-15. Differences were discussed with the
translators, two urologists (BB and JS), and the primary
investigator (TN). Some minor textual changes were made
without changing the content, resulting in the final version
(see supplementary material), which was then backward-
translated by a professional translator with English as native
language. The content validity of the Dutch version was
evaluated in face-to-face interviews with 20 patients.12
Patients were asked to complete the questionnaire.
Afterwards, the content and wording of the questions were
discussed.
2.4 | Measurement properties
The following measurement properties were used to validate
the questionnaire:
2.4.1 | Content validity
The content validity examines the extent to which the items of
the questionnaire measure the concepts of interest in the target
population. Researchers subjectively assessed the correspon-
dence between the questionnaire items and the clinical
symptoms. During the linguistic validation, content validity
was assessed from interviews with patients.12
2.4.2 | Internal consistency
The internal consistency is the correlation between the
different items in the questionnaire and demonstrates if the
items measure the same underlying construct. A Cronbach's
alpha was calculated for the total score and three domains of
the MSISQ-15. A Cronbach's alpha between 0.70 and 0.95
was considered to reflect adequate internal consistency.12
2.4.3 | Reproducibility
The reproducibility is the degree to which scores on a
questionnaire are corresponding in repeated measurements in
stable persons. This was determined by reliability and
agreement. The degree to which patients can be differentiated
from each other, despite the measurement error, reflects the
reliability. The reliability was calculated using the intraclass
correlation coefficient (ICC) for agreement, where ICC scores
over 0.70 are acceptable.12,13 The agreement concerns the
measurement error, that is, the similarity in scores rated on
separate occasions. Differences within the limits of agreement
(LOA) can be interpreted as measurement error. The LOA
were calculated as the mean change in scores of repeated
measurements ±1.96 × standard deviation of the changes.13,14
2.4.4 | Criterion validity
The extent to which questionnaire scores relate to a gold
standard refers to the criterion validity.12 For the MSISQ-15 no
perfect gold standard exists. In the absence of a gold standard the
DutchPISQ-12and theDutch IIEF-15wereused forwomenand
men, respectively. Pearson's correlation coefficient was deter-
mined (range −1 to 1); when values are close to the extremes
indicate either a more negative or positive correlation.12
2.4.5 | Construct validity
The construct validity refers to the extent to which hypotheses
about the scores of the questionnaire relate to other measures.
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Construct validity is considered adequate when at least 75%
of the results of the predefined hypotheses are in
accordance.12
The predefined hypotheses were as follows:
1. The reference group will have lower MSISQ-15 scores
than the patient group.
2. Female patients with lower PISQ-12 scores will have
higher MSISQ-15 scores.
3. Male patients with lower IIEF-15 scores will have higher
MSISQ-15 scores.
4. Patients who score higher on the EQ-VAS will have lower
MSISQ-15 scores.
2.4.6 | Floor and ceiling effects
If more than 15% of the respondents would achieve the lowest
or highest possible score, floor or ceiling effects are
considered.12 The floor and ceiling effects were assessed
for the total and domain scores at baseline in the patient and
reference groups.
2.5 | Statistical methods
Based on the guidelines for validation of question-
naires,12 we aimed at a sample size of 50 MS patients, 50
SCI patients, and 50 control persons. Statistical analysis
was performed using SPSS version 24.0 (IBM Corp.,
Armonk, NY). Continuous data are presented as mean
and standard deviation. Categorical data are presented as
counts and percentages. Differences between the patient
and reference groups or within the patient group, were
tested with the Student's t-tests for continuous variables
and chi-squared tests for categorical variables. Statistical
significance was defined as P-value <0.05.
3 | RESULTS
A total of 106 patients were included in the study. Three
patients were excluded from the analysis because they did
not return the second questionnaire. One patient did not
fully complete the questionnaires and was excluded. Of
the 102 included patients who completed both question-
naires, 49 were female and 53 male. Fifty-three patients
had MS, of whom 36 (68%) relapsing-remitting MS, 6
(11%) primary progressive MS, 8 (15%) secondary
progressive MS, and of 3 (6%) the type of MS was
unknown. Forty-three patients had an SCI and six a cauda
equina syndrome. The SCI patients were classified by the
American Spinal Injury Association (ASIA) impairment
scale15 as follows: 21 (49%) patients ASIA A, 7 (16%)
patients as ASIA B, 4 (9%) patients as ASIA C, 8 (19%)
patients ASIA D, 1 (2%) patient ASIA E, and in 2 (5%)
patients the grade was unknown. The level of SCI was
cervical in 13 (30%), thoracic in 26 (61%), and lumbar in
4 (9%). The reference group consisted of 50 adults, of
whom 29 were female and 21 male. Table 1 shows the
characteristics of the patient and reference groups.
3.1 | Content validity
During the linguistic validation process 12 MS and 8 SCI
patients judged the content validity to be adequate. The
majority confirmed the importance of all questions to assess
the broad range of problems in sexual function with their
neurological condition. Further, they found the Dutch
version clear, understandable, and easy to complete. No
adjustments were necessary.
3.2 | Internal consistency
The MSISQ-15 showed a good internal consistency with
Cronbach's alpha's of >0.8 for test and retest in MS
patients, SCI patients, and total patient group (Table 2).
The internal consistencies for the domains were adequate
with Cronbach's alpha's of >0.7 in the total patient group
and MS patients. In the SCI patients, the primary domain
showed a moderate internal consistency with a Cron-
bach's alpha of 0.53 (test) and 0.55 (retest). The internal
consistency for the secondary and tertiary domains was
good.
3.3 | Reproducibility
The average test-retest period was 20.3 ± 13.8 days,
30.2 ± 25.7 days, 25.1 ± 20.9 days for MS patients, SCI
patients, and total patient group, respectively. The ICCs for
agreement for the total MSISQ-15 and the three domains in
MS patients, SCI patients, and total patient group were all
higher than 0.7, indicating an adequate reliability (Table 3).
Table 3 lists the LOA ranges of the total MSISQ-15 and the
domains.
3.4 | Criterion validity
A significant relationship was found between the total score
of MSISQ-15 and the total score of PISQ-12 in females of the
patient group (test: r=−0.682; retest: r=−0.649, Table 4).
In the male study population, the patient group showed a
significant relationship between the total score of MSISQ-15
and the total score of IIEF-15 (test: r=−0.446; retest:
r=−0.405, Table 4).
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3.5 | Construct validity
All predefined hypotheses were confirmed:
1. The reference group did indeed have lowerMSISQ-
15 scores than the patient group (Table 1).
2 and 3. Female patients with lower PISQ-12 scores and
male patients with lower IIEF-15 indeed had higher
MSISQ-15 scores (criterion validity).
4. In the patient group a significant correlation was
found between the MSISQ-15 score and the
EQ-VAS (Table 4). This confirmed the hypothesis:
“patients who score higher on the EQ-VAS will
have lower MSISQ-15 scores.”
3.6 | Floor and ceiling effects
In the patient group, no floor effects were seen for the total
score, primary domain, and secondary domain (Table 5).
Floor effects were seen in the tertiary domain (19% of the
patients). Ceiling effects were absent in the patient group.
In the reference group, floor effects were found in all the
domains (24-46%). Six (12%) reference persons had the
TABLE 1 Demographic and clinical characteristics presented as mean ± standard deviation or numbers (%)
MS
N= 53a
SCI
N= 49a P-value
Patient group
N= 102a
Reference group
N= 50a P-value
Age, yrs 46.0± 10.1 41.3 ± 11.9 0.034b 43.7 ± 11.2 40.4 ± 15.2 0.135b
Gender
Male 12 (22.6) 41 (83.7) <0.001c 53 (52.0) 21 (42.0) 0.248c
Female 41 (77.4) 8 (16.3) 49 (48.0) 29 (58.0)
Time since diagnosis of
neurogenic disease, yrs
10.1 ± 7.5 13.1 ± 11.7 0.125b 11.5 ± 9.8 – –
Mobility
Fully ambulatory 17 (32.1) 8 (16.3) <0.001c 25 (24.5) – –
Limited walking 31 (58.5) 9 (18.4) 40 (39.2)
Weelchair bound 5 (9.4) 32 (65.3) 37 (36.3)
MSISQ-15 scores baseline
Total score 36.91 ± 12.15 41.04 ± 10.27 0.067b 38.89 ± 11.42 21.14 ± 5.39 <0.001b
Primary domain 13.87 ± 4.67 16.39 ± 3.81 0.004b 15.08 ± 4.44 8.14 ± 2.93 <0.001b
Secondary domain 12.02 ± 4.44 12.08 ± 4.89 0.946b 12.05 ± 4.64 6.84 ± 2.67 <0.001b
Tertiary domain 11.02 ± 5.24 12.57 ± 5.04 0.131b 11.77 ± 5.18 6.16 ± 1.22 <0.001b
PISQ-12 scores baseline 34.36 ± 4.79
N= 41
27.00 ± 3.86
N= 8
<0.001b 33.16 ± 5.37
N= 49
36.17 ± 4.96
N= 29
0.016b
IIEF-15 scores baseline 37.00 ± 21.69
N= 12
41.04 ± 16.83
N= 41
0.497 40.12 ± 17.90
N= 53
55.57 ± 19.58
N= 21
0.002b
EQ-VAS scores baseline 67.91 ± 12.70 69.18 ± 16.64 0.662 68.52 ± 14.67 76.62 ± 14.81 0.002b
aUnless stated otherwise.
bStudent's T-test.
cChi-Square test.
TABLE 2 Cronbach's alpha reflects the internal consistency for the MSISQ-15 total and subscale scores
MS,
N = 53
SCI,
N = 49
Total patient group,
N = 102
Test Re-test Test Re-test Test Re-test
MSISQ-15 total score 0.90 0.91 0.82 0.84 0.87 0.88
MSISQ-15 domains
Primary 0.79 0.78 0.53 0.55 0.70 0.69
Secondary 0.76 0.82 0.79 0.80 0.77 0.81
Tertiary 0.89 0.93 0.89 0.93 0.89 0.93
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lowest possible total score. No ceiling effects were found in
the reference group.
4 | DISCUSSION
After linguistic validation of the original English MSISQ-15
into the Dutch language, we validated its use for patients
with MS and spinal cord disorders such as SCI and cauda
equina syndrome. The measurement properties showed this
Dutch version of the MSISQ-15 to be valid, reliable, and
consistent. This enables physicians to assess the influence
of symptoms of neurological disease on sexual activity and
satisfaction in patients in clinical practice and in research
settings.
The quality of PRO measures for sexual function in
neurological patients was assessed in a recently
published systematic review.3 Strong evidence was found
only for the MSISQ-15/-19 for patients with MS. PRO
measures for patients with SCI showed mostly poor to
fair quality and re-evaluation of all measurement properties
was advised.3 In view of this we chose to validate the Dutch
MSISQ-15 not only in patients with MS, but also in patients
with SCI and cauda equina syndrome. In all these three
conditions, interruption of the spinal cord or the pelvic
autonomic nerves interferes with genital engorgement,
erections, ejaculation, and climax.1,16 Besides the similarity
between the influence of symptoms on sexual function, the
similarity in treatment suggests that the instrument might
work well in those populations.
The good internal consistency of the Dutch MSISQ-15
with Cronbach's alpha's ranging from 0.82 to 0.91 for (re)test
and patient (sub)groups (Table 2) is comparablewith that of the
original MSISQ-15 (total Cronbach's α= 0.92, primary
domain α= 0.87, secondary domain α= 0.82, tertiary domain
α= 0.91).5 The Cronbach's alpha's of all subdomains were
adequate, except for the primary domain in the spinal cord
disorder group (0.53-0.55). The original design of the primary
domain focuses on “MS-related-neurologic changes” that may
directly affect sexual feeling or response. In the spinal cord
disorder group a moderate correlation of the items in the
primary domainwas found. This could have been caused by the
specific well-known problems in SCI patients such as
dissociation between desire, erection, ejaculation, and or-
gasm.16 Another explanation for the moderate correlation
could be the more severe disease-related disability in patients
with a spinal cord disorder. However, during the face-to-face
interviews (linguistic validation process) the SCI patients did
not mention any irrelevant or missing items. Overall, the
internal consistency of the total MSISQ-15 score remains
good.
The reproducibility for the Dutch MSISQ-15 in terms of
test-retest scores was excellent. The mean change betweenTA
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test and retest was ± 0.31 points, demonstrating adequate
agreement. We found an ICC for agreement of 0.88 for the 15
items of the Dutch translation of the MSISQ-15, indicating
good reliability. Comparison with other studies was not
possible, a test-retest was neither performed in the original
MSISQ-15 study5 nor in the MSISQ-19 study.4
Patients and references were good distinguishable as
shown by the confirmation of predefined hypotheses,
confirming discriminative ability and therewith good crite-
rion validity. Furthermore, confirming its use to specifically
deal with sexual problems faced by patients with neurological
disease.
No ceiling effects were found in patients or references. As
expected, floor effects were present in all domains in the
reference group (24-42%). Still, only 6 (12%) references had
the lowest possible MSISQ-15 total score. Remarkable is the
floor effect of the tertiary domain in the patient group (19%).
The tertiary domain items measure the psychological aspects
of SD. Possible explanations for a lowest score are the
duration or acceptance of living with a neurological disease
and having a stable relationship. This could lead to a reduced
reliability and could have effects on the responsiveness.12
Still the reliability was found to be good (ICC tertiary domain
0.85, Table 3).
Analyzing the responsiveness and interpretability of the
MSISQ-15 was not possible because of the short follow-up.
Another limitation of our study was the lack of a golden
standard. In the absence of a validated Dutch measure of
sexual function in neuro-urological patients, we used the
PISQ-12 in women and the IIEF-15 in men. Additionally, the
IIEF-15 assesses erectile dysfunction over the last month in
contrast to the last 6 months of theMSISQ-15. Lastly, treating
physicians were asked to recruit all consecutive patients
meeting the inclusion criteria, but we do not know what
proportion actually participated and what were the reasons for
non-participation.
One of the strengths of our study was the use of
standardizedmeasurement properties to evaluate the reliability
and validity of the MSISQ-15, proposed by Terwee et al.12
Furthermore, our studydesign also allowed testing theMSISQ-
15 in patientswith spinal cord disorders. The results support the
usability of the measure in this population, except when using
the primary domain as subscale on itself. In general, MSISQ-
15 outcomes may support the patient and physician to discuss
SD. We recommend the Dutch physicians to use this measure
in both research and clinical practice to evaluate SD in patients
with MS and spinal cord disorders. Providing that the result of
the primary domain in patients with spinal cord disorders
should be cautiously handled because of the moderate internal
consistency. To assess the urogenital function in neuro-
urological patients we advise to use the MSISQ-15 combined
with the SF-Qualiveen. The SF-Qualiveen is a questionnaire
validated in Dutch to evaluate the urinary-specific quality of
life in MS or SCI patients.17,18
5 | CONCLUSIONS
In conclusion, this Dutch version of MSISQ-15 was tested
following well-established guidelines on measurement
properties and showed good validity and reliability. The
MSISQ-15 allows us to evaluate SD in patients with MS
and spinal cord disorders in both research and clinical
practice.
TABLE 5 Floor and ceiling effects at baseline for the patient and reference groups
Patients n = 102 References n = 50
Floor (%) Ceiling (%) Floor (%) Ceiling (%)
MSISQ-15 total score 1 (1) 0 (0) 6 (12) 0 (0)
MSISQ-15 domains
Primary 3 (3) 0 (0) 12 (24) 0 (0)
Secondary 10 (10) 0 (0) 23 (46) 0 (0)
Tertiary 19 (19) 3 (3) 21 (42) 0 (0)
TABLE 4 Criterion validity of the MSISQ-15 with the PISQ-12 (in females), IIEF-15 (in males), and EQ-VAS
Patients (test) Patients (retest)
rhoa P-value Number rhoa P-value Number
MSISQ-15 vs PISQ-12 −0.682 <0.001 49 −0.649 <0.001 49
MSISQ-15 vs IIEF-15 −0.446 0.001 53 −0.405 0.003 53
MSISQ-15 vs EQ-VAS −0.513 <0.001 102 −0.428 <0.001 102
aPearson's correlation coefficient.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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